BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2025 Earnings Call Transcript

insidermonkey
2025.08.06 12:27
portai
I'm PortAI, I can summarize articles.

BioMarin 制药公司报告了强劲的 2025 年第二季度财报，每股收益为 1.44 美元，超出预期的 1.03 美元。公司实现了两位数的收入增长和显著的盈利扩张。关键进展包括 BMN 333 的推进，这是一种用于治疗软骨发育不全的疗法，以及收购 Inozyme，增强了其酶疗法产品组合。BioMarin 预计将继续增长，并已上调全年收入和收益的指引。管理层对在 2025 年及以后为利益相关者创造价值持乐观态度

Source: insidermonkey The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.